MNCCTN Funding Opportunities
The Minnesota Cancer Clinical Trials Network (MNCCTN) supports cancer-focused research that expands access to clinical trials and strengthens research capacity across Minnesota. Funded by the Minnesota State Legislature through MnDRIVE, MNCCTN operates as a statewide hub network, connecting academic research partners with community oncology sites to bring clinical trials closer to where Minnesotans live and receive care. Through its annual grant program, MNCCTN invests in projects that address Minnesota’s unique cancer burden, foster community-engaged research, and expand a culture of clinical research across the state.
All questions and inquiries should be directed to: [email protected].
Award Categories
Cancer Research Support Grant
Discovery & Planning Grant
FAQs: Guidelines
Do all grant-funded trials need to open through the Network?
The “Expanding Opportunities” pathway does not need to open at MNCCTN sites. All trials are required to enroll participants in Minnesota.
If a trial is open through MNCCTN at MNCCTN sites, can I also enroll my own patients at a non-MNCCTN site?
Yes, but you would need to have outside funding to support and manage enrollment at non-MNCCTN sites.
My proposal might be considered Quality Improvement or administrative in nature, what should I do?
Quality improvement or administrative-related studies will not be funded. If your idea is in a grey area, email MNCCTN to discuss the details ([email protected]).
For awards requiring collaboration with community partners, is there a definition for what this means?
We use the Spectrum of Community Engagement to Ownership framework, which defines engagement on a spectrum from limited involvement to full collaboration. We seek proposals to deepen community engagement from any starting point across this spectrum.
Are there definitions for what MNCCTN considers Diversity, Equity, Inclusion, or Justice focused?
Per the NIH definition “"An underrepresented population refers to a subgroup of the population whose representation is disproportionately low relative to their numbers in the general population, or in the case of clinical trials or patient registries, disease population. The subgroup may be identified by race, ethnicity, age, sex, gender, socioeconomic status, etc.”
I have an idea but no idea how to write a protocol or set up a statistical design - what do I do?
Resources and support can be provided. Reach out to MNCCTN at [email protected]. Another option is to check for the FDA’s next Clinical Investigator Training Course.
FAQs: Logistics
How do I submit?
Check this site once the grant mechanisms are announced for instructions on when and how to apply. All applications will go through InfoReady.
I have a project/trial currently underway. Can I apply for MNCCTN funding to expand my work?
The Therapeutic Trial Expansion pathway is the only grant that allows for research work to already be underway.
What does the grant actually pay for?
The full RFA documents for each award will explain this. Research staff time is covered at MNCCTN sites. If there are questions, reach out to us at [email protected].
I have secured some funding for my project. Can I still apply?
Extra funding must be disclosed and proposals without additional funding will be given priority.
Is there a licensure requirement for applicants?
Applications will be judged based on applicant experience and not on credentials. All appropriate applicants will be considered.
This is exciting, but I'm not ready to submit this year, will these funds be available next year?
Awards will be offered regularly but some may not be offered every year.
Funded Studies
- Stacy D'Andre, MD: “Reishi Mushroom for Treating Aromatase Inhibitor-associated Toxicities: A Double-blind, Randomized Phase 2 Trial"
- Essentia Health & AICAF: "Use of a Clinical Trial Cultural Awareness Tool to Address Organizations Cultural Awareness with American Indian/ Alaska Native-Pilot Project"
- Aasma Shaukat, MD, MPH: "Implementation of proactive colon cancer screening program for the Native American community"
- Amit Kulkarni, MBBS: "A Phase-2 trial testing the safety and feasibility of Restorative Microbiota Therapy (RMT) in patients with steroid refractory severe immune-checkpoint inhibitor induced colitis"
- Jesus Vera Aguilera, MD: "Colchicine for the Management of BRAF/MEK Inhibitor Associated Pyrexia"